International audienceBroadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV envelope glycoprotein gp120 have several features that make them desirable targets for vaccine design. The PGT125-131 bnAb family is of particular interest due to its superior breadth and potency. The overlapping epitopes recognized by this family are intricate and neutralization requires interaction with at least two N-linked glycans (N332/N334, N295 or N301) in addition to backbone-mediated contact with the (323)IGDIR(327) motif of the V3 loop. We have recently shown that this bnAb family consists of two distinct antibody classes that can bind alternate arrangements of glycans in the mannose-patch in the absence of N332 thereby limi...
Stimulating broadly neutralizing antibodies (bnAbs) directly from germline remains a barrier for HIV...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
Despite the isolation of several broadly neutralizing anti-HIV antibodies from infected patients, no...
International audienceBroadly neutralizing antibodies (bnAbs) directed against the mannose-patch on ...
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV en...
Attached is the pre-print of the article that finally appeared in Nature Medicine 18 (11) pp. 1699-1...
The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potent...
<div><p>Understanding the molecular determinants of sensitivity and resistance to neutralizing antib...
AbstractA conserved N-glycan present within the V3 loop of gp120 modulates the sensitivity to neutra...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are p...
Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine. Although ...
International audienceHIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usu...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-in...
Stimulating broadly neutralizing antibodies (bnAbs) directly from germline remains a barrier for HIV...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
Despite the isolation of several broadly neutralizing anti-HIV antibodies from infected patients, no...
International audienceBroadly neutralizing antibodies (bnAbs) directed against the mannose-patch on ...
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV en...
Attached is the pre-print of the article that finally appeared in Nature Medicine 18 (11) pp. 1699-1...
The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potent...
<div><p>Understanding the molecular determinants of sensitivity and resistance to neutralizing antib...
AbstractA conserved N-glycan present within the V3 loop of gp120 modulates the sensitivity to neutra...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are p...
Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine. Although ...
International audienceHIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usu...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-in...
Stimulating broadly neutralizing antibodies (bnAbs) directly from germline remains a barrier for HIV...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
Despite the isolation of several broadly neutralizing anti-HIV antibodies from infected patients, no...